Literature DB >> 21070578

Radical cystectomy for BCG failure: has the timing improved in recent years?

Mark S Soloway1, David Hepps, Devendar Katkoori, Rajinikanth Ayyathurai, Murugesan Manoharan.   

Abstract

OBJECTIVE: • To analyse if there is a trend in recent years towards performing radical cystectomy (RC) before muscle invasion or extravesical spread after failure of bacille Calmette-Guérin (BCG) for high grade Ta/T1 bladder cancer. Although BCG is indicated for prophylaxis after endoscopic tumour resection there is still a risk of progression. PATIENTS AND METHODS: • A retrospective analysis of our RC database (1992-2008) was performed to identify patients who underwent RC after receiving BCG. • Relevant clinical and pathological data for the patients with clinical stage Ta, T1 and/or Tis at initial transurethral resection of bladder tumour were analysed. • Pathological stage and survival for patients undergoing RC from 2003 to 2007 (group 2) were compared with those for patients operated between 1992 and 2002 (group 1).
RESULTS: • A total of 152 patients were included (75 in group 2 and 77 in group 1). Both groups were similar in T-stage before BCG initiation, number of BCG cycles received and time interval to RC. • There was no change in the proportion of patients undergoing RC with ≥ pT2 bladder cancer in recent years (P= 0.5). • Fifty-two percent of group 2 and 43% of group 1 had ≥ pT2 BC. The 5-year survival was similar.
CONCLUSIONS: • Despite concerns about delay in performing RC for patients failing one or more courses of BCG we have not observed a trend towards a lower pathological stage for patients undergoing RC after BCG. • A high proportion of patients have muscle-invasive bladder cancer; more than 10% have lymph node metastasis.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070578     DOI: 10.1111/j.1464-410X.2010.09830.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  [Transitional cell carcinoma of the bladder: bladder-sparing therapy].

Authors:  F Vom Dorp; S Tschirdewahn; T Szarvas; H Rübben; R Kraemer; C Rehme
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

Review 2.  Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited.

Authors:  Matthew J Pagano; Gina Badalato; James M McKiernan
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

Review 3.  Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges.

Authors:  Heather Payne; Andrew Adamson; Amit Bahl; Jonathan Borwell; David Dodds; Catherine Heath; Robert Huddart; Rhona McMenemin; Prashant Patel; John L Peters; Andrew Thompson
Journal:  BJU Int       Date:  2013-11       Impact factor: 5.588

Review 4.  Treatment options in non-muscle-invasive bladder cancer after BCG failure.

Authors:  Nathan A Brooks; Michael A O'Donnell
Journal:  Indian J Urol       Date:  2015 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.